RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: Comparison with inhibitors of HMG-CoA reductase

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 2, 1997, Pages 746-752

  Amin, Dilip ^a,c   Rutledge, Ruth Z ^a   Needle, Saul N ^a   Galczenski, Helen F ^a   Neuenschwander, Kent ^a   Scotese, Anthony C ^a   Maguire, Martin P ^a   Bush, Ray C ^b   Hele, Dave J ^b   Bilder, Glenda E ^a   Perrone, Mark H ^a  

^a Rhône Poulenc Rorer ^*  (United States)

^b Dagenham Research Centre   (United Kingdom)

^c Cardiovascular Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; QUINUCLIDINE DERIVATIVE; RPR 107393; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZARAGOZIC ACID A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MIXTURE; ENANTIOMER; HYPERCHOLESTEROLEMIA; LIVER MICROSOME; MARMOSET; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CALLITHRIX; CHOLESTEROL; CHOLESTYRAMINE; DRUG SYNERGISM; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MEVALONIC ACID; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 8244224541     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. AMIN, D., CORNELL, S. A., GUSTAFSON, S. K., NEEDLE, S. N., BILDER, G. E., ULLRICH, J. W. AND PERRONE, M. H.: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid Res. 33: 1657-1663, 1992.
2. AMIN, D., GUSTAFSON, S. K., WEINACHT, J. M., CORNELL, S. A., NEUENSCHWANDER, K., KOSMIDER, B., SCOTESE, A., REGAN, J. R. AND PERRONE, M. H.: RG 12561 (Dalvastatin): A novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology 46: 13-22, 1993.
3. AMIN, D., NEEDLE, S., RUTLEUDGE, R., GALCZENSKI, H., BUSH, R., HELE, D., MAGUIRE, M., NEUENSCHWANDER, K., SPADA, A., BILDER, G., ROACH, A. AND PERRONE, M.: RPR 107393: A squalene synthase inhibitor and a potent cholesterol-lowering agent. FASEB J. 9: A766, 1995.
4. ASANO, M. AND YAMAKAWA, T.: The fate of branched chain fatty acids in animal body. I. A contribution of the problem of hildebrant acid. J. Biochem. (Tokyo) 37: 321-327, 1950.
5. BAXTER, A., FITZGERALD, B. J., HUTSON, J. L., MCCARTHY, A. D., MOTTERAM, J. M., ROSS, B. C., SAPRA, M., SNOWDEN, M. A., WATSON, N. S., WILLIAMS, R. J. AND WRIGHT, C.: Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J. Biol. Chem. 267: 11705-11708, 1992.
6. BERGSTROM, J. D., DUFRESNE, C., BILLS, G. F., NALLIN-OMSTEAD, M. AND BYRNE, K.: Discovery, biosynthesis, and mechanism of action of the zaragozic acids: Potent inhibitors of squalene synthase. Annu. Rev. Microbiol. 49: 608-639, 1995.
7. BERGSTROM, J. D., KURTZ, M. M., REW, D. J., AMEND, A. M., KARKAS, J. D., BOSTEDOR, R. G., BANSAL, V. S., DUFRESNE, C., VANMIDDLESWORTH, F. L., HENSENS, O. D., LIESCH, J. M., ZINK, D. L., WILSON, K. E., ONISHI, J., MILLIGAN, J. A., BILLS, G., KAPLAN, L., OMSTEAD, N., JENKINS, R. G., HUANG, L., MEINZ, M. S., QUINN, L., BURG, R. W., KONG, Y. L., MOCHALES, S., MOJENA, M., MARTIN, I., PELAEZ, F., DIEZ, M. T. AND ALBERTS, A. W.: Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA 90: 80-84, 1993.
8. BRADFUTE, D. L. AND SIMONI, R. D.: Non-sterol compounds that regulate cholesterogenesis: Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J. Biol. Chem. 269: 6645-6650, 1994.
9. CHIANG, Y.-C. P., BIFTU, T., DOSS, G. A., PLEVYAK, S. P., MARQUIS, R. W., BERGSTROM, J. D., KURTZ, M. M., REW, D. J. AND BERGER, G. D.: Diesters of zaragozic acid A: Synthesis and biological activity. Bioorg. Med. Chem. Lett. 3: 2029-2034, 1993.
10. CIOSEK, C. P., MAGNIN, D. R., HARRITY, T. W., LOGAN, J. V. H., DICKSON, J. K., GORDON, E. M., HAMILTON, K. A., JOLIBOIS, K. G., KUNSELMAN, L. K., LAWRENCE, R. M., MOOKHTIAR, K. A., RICH, L. C., SLUSARCHYK, D. A., SULSKY, R. B. AND BILLER, S. A.: Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem. 268: 4832-24837, 1993.
11. CORRELL, C. C. AND EDWARDS, P. A.: Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro. J. Biol. Chem. 269: 633-638, 1994.
12. CRAIG, C. C., NG, L. AND EDWARDS, P. A.: Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 269: 17390-17393, 1994.
13. CROOK, D., WEISGRABER, K. H., RALL, S. C., JR. AND MAHLEY, R. W.: Isolation and characterisation of several plasma apolipoproteins of common marmoset monkey. Arteriosclerosis 10: 625-632, 1990.
14. ENDO, A., TSUJITA, Y., KURODA, M. AND TANZAWA, K.: Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals. Biochem. Biophys. Acta 575: 266-276, 1979.
15. FOLKERS, K., LANGSJOEN, P., WILLIS, R., RICHARDSON, P., XIA, L. J., YE, C. Q. AND TAMAGAWA, H.: Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA 87: 8931-8934, 1990.
16. GOLDSTEIN, J. L. AND BROWN, M. S.: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
17. GRUNDY, S. M.: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319: 24-33, 1988.
18. KUHN, R., KOHLER, F. AND KOHLER, L.: Uber methyl-oxidationen im tierkorper. Hoppe-Seyler's Z. Physiol. Chem. 242: 171-197, 1936.
19. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. J.A.M.A. 251: 351-362, 1984.
20. LOW, P., ANDERSSON, M., EDLUND, C. AND DALLNER, G.: Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochem. Biophys. Acta 1165: 102-109, 1992.
21. NEEDLE, S., RUTLEDGE, R., BUSH, R., BILDER, G., PERRONE, M. AND AMIN, D.: Comparison of squalene synthase inhibitory activity of two enantiomers of RPR 107393. FASEB J. 9: A195, 1995.
22. NESS, G. C., EALES, S., LOPEZ, D. AND ZHAO, Z.: Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression by sterols and nonsterols in rat liver. Arch. Biochem. Biophys. 308: 420-425, 1994.
23. PANINI, S. R., EVERSON, G. T. AND SPENCER, T. A.: Effects of specific inhibition of sterol biosynthesis on the uptake and utilization of low density lipoprotein cholesterol by HepG2 cells. J. Lipid Res. 32: 1657-1663, 1991.
24. RODWELL, V. W., NORDSTROM, J. L. AND MITSCHELEN, J. J.: Regulation of HMG-CoA reductase. Adv. Lipid Res. 14: 1-74, 1976.
25. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag, New York, 1987.
26. The Cholesterol Facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: A joint statement by the American Heart Association and the National Heart, Lung and Blood Institute. Circulation 81: 1721-1733, 1990.
27. TSUJITA, Y., KURODA, M., SHIMADA, Y., TANZAWA, K., ARAI M., KANEKO, I., TANAKA, M., MASUDE, H., TARUMI, C., WATANABE, Y. AND FUJII, S.: CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochem. Biophys. Acta 877: 50-60, 1986.
28. WILLIS, R. A., FOLKERS, K., TUCKER, J. L., YE, C. Q., XIA, L. J. AND TAMAGAWA, H.: Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. USA 87: 8928-8930, 1990.